Cue Biopharma Files 8-K: Other Events

TL;DR

Cue Biopharma filed an 8-K for 'Other Events' on 4/1/26. Details TBD.

AI Summary

On April 1, 2026, Cue Biopharma, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant business updates beyond the reporting of an event on the specified date.

Why It Matters

This filing indicates a corporate event occurred on April 1, 2026, requiring disclosure, though the specifics are not detailed in the provided summary.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' without immediate disclosed financial impact or significant operational changes.

Key Players & Entities

• Cue Biopharma, Inc. (company) — Filer of the 8-K report
• 0001645460 (company) — CIK number for Cue Biopharma, Inc.
• 2026-04-01 (date) — Period of Report for the 8-K filing
• 2026-04-07 (date) — Filing Date and Acceptance Date of the 8-K

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
• $7.5 million — preclinical milestone event triggers a $7.5 million payment to the Company, which is expect

Filing Documents

• cue-20260401.htm (8-K) — 65KB
• 0001193125-26-144569.txt ( ) — 194KB
• cue-20260401.xsd (EX-101.SCH) — 45KB
• cue-20260401_htm.xml (XML) — 4KB

01

Item 8.01. Other Events On April 1, 2026, Cue Biopharma, Inc. (the "Company") received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved selection of its first compound for lead optimization under the Collaboration and License Agreement entered into with Boehringer Ingelheim on April 10, 2025 for the research, development and commercialization of differentiated B cell depletion molecules, including the Company's CUE-501 product candidate. This preclinical milestone event triggers a $7.5 million payment to the Company, which is expected to be received in May 2026. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the timing of a preclinical milestone payment expected to be received by the Company. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "anticipate," "believe," "continue," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "seek," "strategy," "future," "vision," "should," "target," "will," "would," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's limited operating history, limited cash and a history of losses; the Company's ability to achieve profitabili

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: April 7, 2026 By: /s/ Lucinda Warren Name: Lucinda Warren Title: Interim President and Chief Executive Officer